# Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)

> **NCT00407186** · PHASE3 · UNKNOWN · sponsor: **Dutch Colorectal Cancer Group** · enrollment: 788 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** cisplatin+capecitabine
- **RADIATION:** radiotherapy
- **DRUG:** epirubicin+cisplatin+capecitabine

## Key facts

- **NCT ID:** NCT00407186
- **Lead sponsor:** Dutch Colorectal Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-01-11
- **Primary completion:** 2018-12
- **Final completion:** 2025-12
- **Target enrollment:** 788 (ACTUAL)
- **Last updated:** 2017-10-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407186, "Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00407186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*